| Autor: |
Jamee, Mahnaz, Farsi, Yeganeh, Akhondi, Amir Hossein, Kamali, Farnaz, Hajialigol, Amir Hossein, Mirzaee, Mahbubeh, Mohkam, Masoumeh |
| Předmět: |
|
| Zdroj: |
Journal of Pediatric Nephrology; Summer2022, Vol. 10 Issue 3, p103-111, 9p |
| Abstrakt: |
Eculizumab is a humanized monoclonal antibody targeting the C5 (complement 5) member of complement proteins and inhibiting its cleavage to C5a and C5b. Eculizumab has been proven to be effective in a wide array of nephrologic, neurologic, and hematologic pediatric disorders. Kidney disorders, particularly those with immune-mediated pathomechanism, are the most common indications of eculizumab, including atypical hemolytic uremic syndrome (aHUS), hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (MPGN), immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and less commonly post-infectious glomerulonephritis and diffuse proliferative lupus nephritis. In this review, we aimed to summarize the current evidence on approved and off-label applications of eculizumab and their specific considerations in pediatric kidney disorders. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
